EGFR and neoplasm: Concentration-dependent reductions in both cell viability and tumor uptake were observed when this model was treated with Erlotinib, a molecular agent targeting the tyrosine-kinase domain of the EGFR, which further reinforces the nanobody’s promisingly high affinity and receptor specificity [48].